Mutations in the EGFR: The importance of genotyping

Douglas K. Price*, William D. Figg

*Corresponding author for this work

Research output: Contribution to journalShort surveypeer-review

7 Scopus citations


Gefitinib reached the clinic with anticipation, but initial clinical trials were disappointing with only a small number of patients showing response to treatment. In two recent articles published simultaneously, Lynch et al., and Paez et al. help to explain those initial clinical findings. Both groups report that somatic mutations found within the coding region of the EGFR may predict the sensitivity to gefitinib treatment.

Original languageEnglish
Pages (from-to)434-435
Number of pages2
JournalCancer Biology and Therapy
Issue number5
StatePublished - May 2004
Externally publishedYes


  • EGFR
  • Gefitinib
  • Genotype
  • Lung cancer
  • Mutation


Dive into the research topics of 'Mutations in the EGFR: The importance of genotyping'. Together they form a unique fingerprint.

Cite this